about
MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCUA general framework for quantifying the effects of DNA repair inhibitors on radiation sensitivity as a function of doseA new procedure for determining the genetic basis of a physiological process in a non-model species, illustrated by cold induced angiogenesis in the carpSpectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma.hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.Gene expression analysis in human breast cancer associated blood vessels.Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.RIPOSTE: a framework for improving the design and analysis of laboratory-based research.Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapyA core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia.Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3.FANCD2 limits replication stress and genome instability in cells lacking BRCA2.Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation.Informed consent, biobank research, and locality: perceptions of breast cancer patients in three European countries.Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells.Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer.RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73.A Monte-Carlo method for interface dosimetry of beta emitters.Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas.Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma.Intensity-modulated Radiotherapy Allows Escalation of the Radiation Dose to the Pelvic Lymph Nodes in Patients with Locally Advanced Prostate Cancer: Preliminary Results of a Phase I Dose Escalation StudyModeling genotypes in their microenvironment to predict single- and multi-cellular behaviorGuidelines for using sigQC for systematic evaluation of gene signatures
P50
Q21136391-2EBB8120-BE77-40AC-8D7A-266676E072CCQ21245223-7CFB2472-520F-4810-B5EC-56BD2AD481FAQ33512121-B55A3EEB-B752-4D36-9B12-047983342181Q33574427-1FA6100B-C1FD-4D64-8327-F5BEA2BA8BEBQ34100816-982FAE52-4283-40E7-ABD4-C34754CAAACDQ34440820-E397B47F-074A-41EA-985A-5E958E9CF6A9Q34628919-5BF6D5C4-FDFD-4328-A0C3-54FEE111980BQ35204515-1DED2D68-1756-4239-B6C2-12BF42E174A3Q35709066-96524146-18EA-4FDC-A2F9-1E0A98FFC791Q36768782-4FD3E54B-6DA4-491F-AB34-3D2716BFC017Q37094321-5F9325AD-047A-4DC6-A540-7FE257886112Q37231848-EB6045EE-94A9-479C-8474-F0C023AB27FBQ37591415-766653E4-F5BE-4EC1-B94B-7534519002E3Q38263008-80B9BC42-48CD-4792-A261-E0B2BBD0B005Q38318195-1DD207CE-96FE-4C7E-B84D-8480F5F609FAQ38763307-3592679C-A328-42E0-B03F-7B2C54E46535Q38821010-ACEA1100-8317-4DD3-80F7-ECE629250290Q38952562-1CB1A2FA-11C9-49D8-985A-AE9E069F0A48Q39032106-9348CB0E-DC2A-4C8F-AC53-04F6E7CDC04BQ39239858-9275E30B-B77E-48B7-A3B9-EC9462F37514Q39779546-DEDFEC9A-537F-40F5-A789-F3B6E1C1A2C1Q41115565-9B22A8A6-E9A4-429A-987A-7C888478F7E9Q48139101-4B2E0017-0223-42E2-A8D8-D94B291F7239Q51828903-11A33B90-763D-448D-83E9-37B5B2FB4791Q51988092-654962CD-1CF1-43D4-A191-C9935221F633Q54293758-6EDCE825-7B07-448E-AC84-EBFCB646D9EBQ57694439-59E33A5D-141D-4C19-8FA8-759F0C7832F3Q64269457-EFBADE9B-3E59-47B5-AD2F-F087613BAB9FQ93012478-761ED61B-A07E-46E9-8DB5-99B1B571407E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesca Buffa
@fr
Francesca M Buffa
@es
Francesca M Buffa
@nl
Francesca M Buffa
@sl
Francesca M. Buffa
@en
type
label
Francesca Buffa
@fr
Francesca M Buffa
@es
Francesca M Buffa
@nl
Francesca M Buffa
@sl
Francesca M. Buffa
@en
prefLabel
Francesca Buffa
@fr
Francesca M Buffa
@es
Francesca M Buffa
@nl
Francesca M Buffa
@sl
Francesca M. Buffa
@en
P1053
D-2574-2013
P106
P21
P31
P3829
P496
0000-0003-0409-406X